RT Journal Article
SR Electronic
T1 A population scale analysis of rare <em>SNCA</em> variation in the UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.11.20172866
DO 10.1101/2020.08.11.20172866
A1 Blauwendraat, Cornelis
A1 Makarious, Mary B.
A1 Leonard, Hampton L.
A1 Bandres-Ciga, Sara
A1 Iwaki, Hirotaka
A1 Nalls, Mike A.
A1 Noyce, Alastair J
A1 Singleton, Andrew B.
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.11.20172866.abstract
AB Parkinson’s disease (PD) is a complex neurodegenerative disease with a variety of genetic and environmental factors contributing to disease. The SNCA gene encodes for the alpha-synuclein protein which plays a central role in PD, where aggregates of this protein are one of pathological hallmarks of disease. Rare point mutations and copy number gains of the SNCA gene have been shown to cause autosomal dominant PD and common DNA variants identified using GWAS are a moderate risk factor for PD. The UK Biobank is a large prospective study including ~500,000 individuals and has revolutionized human genetics. Here we assessed the frequency of SNCA variation in this cohort and identified 26 subjects carrying variants of interest including duplications (n=6), deletions (n=6) and large complex likely mosaic events (n=14). No known pathogenic missense variants were identified. None of these subjects were reported to be a PD case, although it is possible that these individuals may develop PD at a later age, and whilst three had known prodromal features, these did not meet defined thresholds for being considered ‘prodromal’ cases. Four of the 14 large complex carriers showed a history of blood based cancer. Overall, we identified copy number variants in the SNCA region in a large population based cohort without reported PD phenotype and symptoms. Putative mosaicism of the SNCA gene was identified, however it is unclear whether it is associated with Parkinson's disease. These individuals are potential candidates for further investigation by performing SNCA RNA and protein expression studies, as well as promising clinical trial candidates to understand how duplication carriers potentially escape PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the Intramural Research Program of the NIH, National institute on Aging.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:exemptionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used here is publically available upon application from the UK Biobank (https://www.ukbiobank.ac.uk/)